DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia

Blood Cancer Journal

Volumn 1, Issue 3, 2011, Pages

  Ewalt, M ^a   Galili, N G ^a   Mumtaz, M ^a   Churchill, M ^a   Rivera, S ^a   Borot, F ^a   Raza, A ^a   Mukherjee, S ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE 3A; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; DNA METHYLATION; EXON; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; LETTER; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; REFRACTORY ANEMIA WITH EXCESS BLASTS; SOMATIC MUTATION; TRANSFUSION;

EID: 79960257531     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.7     Document Type: Letter

References (8)

1. Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004; 104: 3527-3534. (Pubitemid 39564423)
2. Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007; 21: 2258-2263. (Pubitemid 350011697)
3. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H et al. Improved expression and reactivity of transduced tumorspecific TCRs in human lymphocytes by pecific silencing of endogenous TCR. Cancer Res 2009; 69: 9003-9011.
4. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-293. (Pubitemid 30017254)
5. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009; 113: 66-74.
6. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079. (Pubitemid 24328100)
7. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S et al. Identification of therapeutic targets for quiescent, chemotherapy- resistant human leukemia stem cells. Sci Transl Med 2010; 2: 17ra9.
8. Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 2003; 75: 1429-1436. (Pubitemid 36597272)